PubMed Journal Database | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation RSS

01:53 EDT 25th March 2019 | BioPortfolio

The US National Library of Medicine and National Institutes of Health manage which comprises of more than 29 million records, papers, reports for biomedical literature, including MEDLINE, life science and medical journals, articles, reviews, reports and  books.

BioPortfolio aims to cross reference relevant information on published papers, clinical trials and news associated with selected topics - speciality.

For example view all recent relevant publications on Epigenetics and associated publications and clincial trials.

Showing PubMed Articles 1–25 of 543 from Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

A tale of two eras: the story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphoma.

Comparison of graft-acquisition and early direct charges of haploidentical related donor transplantation versus umbilical cord blood transplantation.

Alternative donor allogeneic hematopoietic cell transplants (allo-HCT), such as double UCB transplants (dUCBT) and haploidentical related donor transplants (haplo-HCT) have been shown to be safe and effective in adult patients who do not have an HLA-identical sibling or unrelated donor available. Most transplant centers have committed to one of the two alternative donor sources, even though there is a lack of published randomized data directly comparing outcomes and comparative data on cost effectiveness of...

Protecting the selfless:towards more comprehensive care for pediatric related stem cell donors.


Clearance of hematological malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions.

Well-established donor lymphocyte infusion (DLI) and novel cytokine-induced killer (CIK) cell therapy for the treatment of relapsing hematological malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) were compared with respect to their feasibility, safety and efficacy. Altogether, a total of 221 infusions were given to 91 patients (DLI, n=55; CIK, n=36). T cell recovery was significantly improved after CIK cell therapy (P

Screening for family psychosocial risk in pediatric hematopoietic stem cell transplantation with The Psychosocial Assessment Tool (PAT).

Family psychosocial risk screening is an important initial step in delivering evidence-based care in hematopoietic stem cell transplantation (HCT). Establishing an evidence-based screening approach that is acceptable, reliable and valid is an essential step in psychosocial care delivery.

Standard ATG Dosing Results in Poorer Outcomes in Overexposed Patients after Ex vivo CD34 Selected Allogeneic Hematopoietic Cell Transplantation.

Anti-thymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric weight-based dosing of ATG, used to prevent graft rejection in ex vivo CD34-selected allo-HCT, may lead to serious adverse consequences on outcomes in certain patients. We evaluated 304 patients undergoing myeloabl...

Nutritional and post-transplantation outcomes of enteral versus parenteral nutrition in pediatric hematopoietic stem cell transplantation: a systematic review of randomized and non-randomized studies.

Hematopoietic stem cell transplantation (HSCT) involves the administration of chemotherapy followed by the infusion of donor stem cells. After treatment, children can consequently experience nausea, vomiting, diarrhea, anorexia and mucositis, which negatively impact oral intake leading to rapid deterioration in nutritional status and risk of malnutrition. Nutrition support therefore becomes necessary to circumvent these adverse effects. This has traditionally been provided via parenteral nutrition (PN), but...

Donor specific anti-HLA antibodies (DSA) in Haploidentical stem cell transplantation with Post Transplant Cyclophosphamide: risk of graft failure, poor graft function and impact on outcomes.

The presence of donor-specific anti-HLA antibodies (DSA) is associated with a 10-fold increased risk of graft failure in haploidentical stem cell transplantation (Haplo-SCT). The Consensus Guidelines from the European Society for Blood and Marrow Transplantation (EBMT) set a Mean Fluorescence Intensity (MFI) > 1000 as a cut-off for DSA positivity. In the absence of an alternative donor, it is recommended that patients undergo desensitization therapy, especially with high DSA levels (>5,000 MFI). The aim of ...

Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups.

The choice of alternative donor is a major issue in allogeneic hematopoietic stem cell transplantation for patients with primary myelofibrosis (PMF) who have no HLA-matched related donor. A retrospective study was conducted using the national registry data of 224 PMF patients to compare the outcomes of first allogeneic transplantation from HLA-matched related donor bone marrow (Rtd-BM), HLA-matched related donor peripheral blood stem cells (Rtd-PB), HLA-matched unrelated donor bone marrow (UR-BM), unrelated...

Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results.

Although bortezomib and rituximab have synergistic activity in patients with lymphoma, and can both attenuate graft-versus-host disease (GVHD), the drugs have not been used together in patients undergoing allogeneic stem-cell transplantation (alloSCT). In this phase 1/2 trial, we assessed the safety and activity of bortezomib added to the rituximab (R) plus BEAM (carmustine, etoposide, cytarabine, melphalan) regimen in patients with relapsed lymphoma undergoing alloSCT. Primary GVHD prophylaxis consisted of...

Risk Factors for Development of and Progression of Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.

Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell transplantation (HSCT), most commonly associated with high-intensity chemotherapies. Since development of VOD/SOS may be rapid and unpredictable, the importance of identifying risk factors to facilitate prompt diagnosis and timely treatment has become increasingly well recognized. Reporting of new retrospective study data for adul...

A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplant Patients, Caregivers and Families.

Patient, caregiver and family education and support was one of six key areas of interest identified by the National Marrow Donor Program (NMDP)/Be The Match two-year project to prioritize patient centered outcomes research (PCOR) goals for the blood and marrow transplant (BMT) community. PCOR focuses on research to help patients and their caregivers make informed decisions about health care. Therefore, each area of interest was assigned to a Working Group with broad representation, including patients, careg...

Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation.

We analyzed data of 64,539 consecutive patients in the national Japanese transplant registry, including 40,195 after allogeneic stem cell transplantation, 24,215 after autologous stem cell transplantation, and 129 after syngeneic stem cell transplantation, and 299 developed Epstein-Barr virus positive post-transplant lymphoproliferative disorder. The probability at 2 years was 0.79% after allogeneic transplantation, 0.78% after syngeneic transplantation, and 0.11% after autologous transplantation. The follo...


Multiple sclerosis (MS) is a chronic, disabling, immune-mediated, central nervous system demyelinating and degenerative disease. Approved disease modifying therapies may be incompletely effective in some patients with highly active relapsing disease and high risk of disability. Immunoablative or myeloablative therapy followed by autologous hematopoietic cell transplantation (AHCT) has been investigated in retrospective studies, clinical trials, and meta-analyses/systematic reviews as an approach to address ...

Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades.

The curative potential of autologous hematopoietic cell transplantation (autoHCT) for male germ cell tumors (GCT) is well established. Optimal timing and number (single, ST vs. tandem, TT vs. three) of autoHCT are controversial with wide practice variation.

Non-myeloablative Matched Sibling Donor Hematopoietic Cell Transplantion in Children and Adolescents with Sickle Cell Disease.

Sickle cell disease (SCD) is a potentially debilitating hemoglobinopathy associated with early mortality. The only established curative therapy is hematopoietic cell transplantation (HCT)with a matched sibling donor (MSD). The National Institutes of Health (NIH) nonmyeloablative regimen of alemtuzumab/300 cGy total body irradiation and prolonged sirolimus exposure for graft-versus-host disease (GVHD) prophylaxis was administered to 16 children and adolescents. Infused products were unmanipulated G-CSF mobil...

Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future.

Allogenic hematopoietic stem cell transplantation (HSCT) has been shown to be a treatment option for a selected group of patients with mucopolysaccharidoses (MPS) (MPS I, II, IVA, VI, and VII). Early diagnosis and timely referral to an expert in MPS are critical, followed by a complete examination and evaluation with a multidisciplinary team, including a transplant physician. Treatment recommendations for MPS are based on multiple factors such as biological, sociological, and financial effects. These includ...

Utilization and outcomes of fertility preservation techniques in women undergoing allogeneic hematopoietic cell transplant.

Iatrogenic menopause with consequent infertility is a major complication in reproductive aged women undergoing hematopoietic cell transplantation (HCT). Recent guidelines recommend a discussion of the possibility of infertility and the options for fertility preservation as part of informed consent before initiation of any cancer-directed therapy, including HCT. Women aged 15-49 years at the time of allogeneic HCT, between the years 2001 and 2017, were identified from the Mayo Clinic Rochester institutional ...

Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation.

The different effects of pre-engraftment syndrome (PES) and acute graft-versus-host disease (GVHD) on transplant outcomes after cord blood transplantation (CBT) are unclear. We retrospectively evaluated the impact of PES and acute GVHD on relapse and survival after single CBT for 138 adult patients with hematological malignancies in our institute between 2004 and 2016. Multivariate analysis demonstrated that development of grade III to IV acute GVHD, particularly gut or liver involvement of acute GVHD, sign...

Improved survival after cord blood transplantation: single center experience in pediatric patients over a two-decade period.

Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-based Analysis.

Access to hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) is primarily dependent on disease-related factors but may be influenced by social and economic determinants.

The Roles of FDG PET-CT in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy Treating Patients with Non-Hodgkin Lymphoma.

CD19-targeting chimeric antigen receptor (CAR) T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), but has been associated with serious adverse effects such as cytokine release syndrome (CRS). It has been speculated that NHL baseline disease burden might affect clinical outcome and CRS, but such assumption has not been explored in detail. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG), as measured by FDG PET-CT, are quantitative indicators...

Barriers to Allogeneic Hematopoietic Stem Cell Transplant for Human T-Cell Lymphotropic Virus 1 associated Adult T-Cell Lymphoma-Leukemia in the United States: Experience from a large cohort in a major tertiary center.

In the United States (U.S.), Adult T-Cell Lymphoma-Leukemia (ATLL) carries a dismal prognosis and mainly affects immigrants from Human T-Cell Lymphotropic Virus 1 (HTLV-1) endemic areas. Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) can be effective and is recommended as an upfront treatment in the NCCN guidelines. We studied the barriers to alloHSCT in one of the largest ATLL populations in the U.S. Comprehensive chart and donor registry reviews were conducted for 88 ATLL patients treated at Mon...

Survivor and Clinician Assessment of Survivorship Care Plans for Hematopoietic Stem Cell Transplant Patients: An Engineering, Primary Care, and Oncology Collaborative for Survivorship Health.

The long-term care of hematopoietic stem cell transplant (HSCT) survivors poses special challenges due to a myriad of possible chronic and/or late complications. Survivorship care plans (SCPs) have been proposed as a tool to communicate information regarding the late effects of treatment and recommended follow-up care to clinicians and survivors. Our primary objective was to determine SCP content and format as well as to assess preferred timing of SCP provision following HSCT.

Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma.

We analyzed 186 patients with lymphoma who received allogeneic stem cell transplant (ASCT) with fludarabine-melphalan (FM) conditioning and different donors [25 haploidentical (HD), 98 matched unrelated (MUD), and 63 matched related (MRD)] at our institution between 09/2009-01/2018. Patients received fludarabine 160 mg/m (40 mg/m/day x 4 days) in combination with one dose of melphalan 140 mg/m (FM140) or 100 mg/m2 (FM100). Engraftment was similar between the 3 groups (92%, 89%, and 98%, respectively; p...

Quick Search